Bengaluru, January 15, 2026 – Biocon Limited (BSE: 532523 | NSE: BIOCON) on Wednesday announced the successful allotment of equity shares under its recently concluded institutional fundraise, mobilising ₹4,150 crore to strengthen its balance sheet and support long-term growth initiatives.
Issue Details and Fundraise Summary
The company approved the issue and allotment of 11,26,64,585 equity shares of face value ₹5 each at an issue price of ₹368.35 per share, including a premium of ₹363.35 per share. The institutional placement opened on January 12, 2026, and closed on January 14, 2026.The total amount raised through the transaction aggregates to ₹4,150 crore.
Key Issue Particulars
| Particulars | Details |
|---|---|
| Securities issued | Equity shares |
| Number of shares allotted | 11,26,64,585 |
| Issue price | ₹368.35 per share |
| Face value | ₹5 per share |
| Total proceeds | ₹4,150 crore |
Impact on Share Capital
Following the allotment, Biocon’s paid-up equity share capital increased from ₹754.12 crore, comprising 150.82 crore equity shares, to ₹810.45 crore, comprising 162.09 crore equity shares of face value ₹5 each.Share Capital Position
| Particulars | Before Issue | After Issue |
|---|---|---|
| Paid-up equity capital | ₹754.12 crore | ₹810.45 crore |
| Number of equity shares | 150.82 crore | 162.09 crore |
Institutional Participation Highlights
The issue saw participation from several large domestic mutual fund schemes, with select funds receiving more than 5 percent of the equity shares offered in the transaction. Major allocations were seen across diversified, value, healthcare-focused, and large-and-midcap oriented schemes, reflecting continued institutional confidence in Biocon’s long-term business prospects.Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.